Advances in Immuno-Oncology Therapeutics for Metastatic Triple-Negative Breast Cancer

Engage with this series of 4 focused ClinicalThought commentaries to gain expert insight on how to optimally integrate immunotherapy into the care of your patients with metastatic TNBC.
Sarah Donahue, MPH, NP
David B. Page, MD
Hope S. Rugo, MD
Peter Schmid, MD, PhD, FRCP


Review the latest developments in immuno-oncology strategies for managing metastatic TNBC with this set of expert commentaries, including optimal use of immune checkpoint inhibition, management of immune-related toxicities, and future directions.

Sarah Donahue, MPH, NP David B. Page, MD Hope S. Rugo, MD Peter Schmid, MD, PhD, FRCP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 14, 2020 Expired: May 13, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?